Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice
Aberrant activation of the latent transcription factor STAT3 and its downstream targets is a common feature of epithelial-derived human cancers, including those of the gastrointestinal tract. Mouse models of gastrointestinal malignancy implicate Stat3 as a key mediator of inflammatory-driven tumorig...
Saved in:
Published in | Molecular cancer therapeutics Vol. 13; no. 2; pp. 468 - 474 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.02.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Aberrant activation of the latent transcription factor STAT3 and its downstream targets is a common feature of epithelial-derived human cancers, including those of the gastrointestinal tract. Mouse models of gastrointestinal malignancy implicate Stat3 as a key mediator of inflammatory-driven tumorigenesis, in which its cytokine/gp130/Janus kinase (Jak)-dependent activation provides a functional link through which the microenvironment sustains tumor promotion. Although therapeutic targeting of STAT3 is highly desirable, such molecules are not available for immediate clinical assessment. Here, we investigated whether the small-molecule Jak1/2 inhibitor AZD1480 confers therapeutic benefits in two mouse models of inflammation-associated gastrointestinal cancer, which are strictly dependent of excessive Stat3 activation. We confirm genetically that Cre-mediated, tumor cell-specific reduction of Stat3 expression arrests the growth of intestinal-type gastric tumors in gp130(F/F) mice. We find that systemic administration of AZD1480 readily replicates this effect, which is associated with reduced Stat3 activation and correlates with diminished tumor cell proliferation and increased apoptosis. Likewise, AZD1480 therapy also conferred a cytostatic effect on established tumors in a colitis-associated colon cancer model in wild-type mice. As predicted from our genetic observations in gp130(F/F) mice, the therapeutic effect of AZD1480 remains fully reversible upon cessation of compound administration. Collectively, our results provide the first evidence that pharmacologic targeting of excessively activated wild-type Jak kinases affords therapeutic suppression of inflammation-associated gastrointestinal cancers progression in vivo. |
---|---|
AbstractList | Aberrant activation of the latent transcription factor STAT3 and its downstream targets is a common feature of epithelial-derived human cancers, including those of the gastrointestinal tract. Mouse models of gastrointestinal malignancy implicate Stat3 as a key mediator of inflammatory-driven tumorigenesis, in which its cytokine/gp130/Janus kinase (Jak)-dependent activation provides a functional link through which the microenvironment sustains tumor promotion. Although therapeutic targeting of STAT3 is highly desirable, such molecules are not available for immediate clinical assessment. Here, we investigated whether the small-molecule Jak1/2 inhibitor AZD1480 confers therapeutic benefits in two mouse models of inflammation-associated gastrointestinal cancer, which are strictly dependent of excessive Stat3 activation. We confirm genetically that Cre-mediated, tumor cell-specific reduction of Stat3 expression arrests the growth of intestinal-type gastric tumors in gp130(F/F) mice. We find that systemic administration of AZD1480 readily replicates this effect, which is associated with reduced Stat3 activation and correlates with diminished tumor cell proliferation and increased apoptosis. Likewise, AZD1480 therapy also conferred a cytostatic effect on established tumors in a colitis-associated colon cancer model in wild-type mice. As predicted from our genetic observations in gp130(F/F) mice, the therapeutic effect of AZD1480 remains fully reversible upon cessation of compound administration. Collectively, our results provide the first evidence that pharmacologic targeting of excessively activated wild-type Jak kinases affords therapeutic suppression of inflammation-associated gastrointestinal cancers progression in vivo. Aberrant activation of the latent transcription factor STAT3 and its downstream targets is a common feature of epithelial-derived human cancers, including those of the gastrointestinal tract. Mouse models of gastrointestinal malignancy implicate Stat3 as a key mediator of inflammatory-driven tumorigenesis, in which its cytokine/gp130/Janus kinase (Jak)–dependent activation provides a functional link through which the microenvironment sustains tumor promotion. Although therapeutic targeting of STAT3 is highly desirable, such molecules are not available for immediate clinical assessment. Here, we investigated whether the small-molecule Jak1/2 inhibitor AZD1480 confers therapeutic benefits in two mouse models of inflammation-associated gastrointestinal cancer, which are strictly dependent of excessive Stat3 activation. We confirm genetically that Cre-mediated, tumor cell–specific reduction of Stat3 expression arrests the growth of intestinal-type gastric tumors in gp130F/F mice. We find that systemic administration of AZD1480 readily replicates this effect, which is associated with reduced Stat3 activation and correlates with diminished tumor cell proliferation and increased apoptosis. Likewise, AZD1480 therapy also conferred a cytostatic effect on established tumors in a colitis-associated colon cancer model in wild-type mice. As predicted from our genetic observations in gp130F/F mice, the therapeutic effect of AZD1480 remains fully reversible upon cessation of compound administration. Collectively, our results provide the first evidence that pharmacologic targeting of excessively activated wild-type Jak kinases affords therapeutic suppression of inflammation-associated gastrointestinal cancers progression in vivo. Mol Cancer Ther; 13(2); 468–74. ©2014 AACR. |
Author | Ernst, Matthias Thiem, Stefan Waring, Paul M Buchert, Michael Stuart, Emma Farid, Ryan Huszar, Dennis Elzer, Joachim Putoczki, Tracy Phesse, Toby J |
Author_xml | – sequence: 1 givenname: Emma surname: Stuart fullname: Stuart, Emma email: Matthias.Ernst@wehi.edu.au organization: Corresponding Author: Matthias Ernst, The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC 3052, Australia. Matthias.Ernst@wehi.edu.au – sequence: 2 givenname: Michael surname: Buchert fullname: Buchert, Michael – sequence: 3 givenname: Tracy surname: Putoczki fullname: Putoczki, Tracy – sequence: 4 givenname: Stefan surname: Thiem fullname: Thiem, Stefan – sequence: 5 givenname: Ryan surname: Farid fullname: Farid, Ryan – sequence: 6 givenname: Joachim surname: Elzer fullname: Elzer, Joachim – sequence: 7 givenname: Dennis surname: Huszar fullname: Huszar, Dennis – sequence: 8 givenname: Paul M surname: Waring fullname: Waring, Paul M – sequence: 9 givenname: Toby J surname: Phesse fullname: Phesse, Toby J – sequence: 10 givenname: Matthias surname: Ernst fullname: Ernst, Matthias |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24398427$$D View this record in MEDLINE/PubMed |
BookMark | eNo9kMtOAyEUhompsbb6CjpLN1M5MDPA0jReU-OmbiUMhRbtzFRgTPr2Utu6IIfk_84l3wgN2q41CF0DngCU_BZKWuYMKjppdMyB5rjkNI8n6DwlPOclFIO__54aolEInxgDFwTO0JAUVPCCsHP0MV8Zrzamj05nrl252kXXtVlnsxf1lSkd3Y-L22MUso3vlt6EcICWKkTfuTaaEF2r1lnsm86HxGeN0-YCnVq1DubyUMfo_eF-Pn3KZ2-Pz9O7Wa4LTmKuBDCCQWMGoqpsbTFfWFHVhiihOGCMLRN1BTZxmuEUKCiBk8pixRixdIxu9nPTed99ukU2LmizXqvWdH2QUAiRHqFFQtke1b4LwRsrN941ym8lYLmTK3fa5E6bfJ3OJVC5kyvnqfPqsKSvG7P47zvapL_rsnlp |
CitedBy_id | crossref_primary_10_1016_j_jbior_2014_05_004 crossref_primary_10_1016_j_semcancer_2019_09_022 crossref_primary_10_1186_s13578_018_0248_9 crossref_primary_10_3390_nu11092001 crossref_primary_10_1126_science_aan3975 crossref_primary_10_1158_2326_6066_CIR_19_0623 crossref_primary_10_3390_cancers14020264 crossref_primary_10_1093_carcin_bgx080 crossref_primary_10_1186_s12885_018_4071_9 crossref_primary_10_3390_cancers16030492 crossref_primary_10_1111_jgh_13297 crossref_primary_10_1016_j_yexcr_2022_113079 crossref_primary_10_15252_emmm_201809539 crossref_primary_10_1586_17512433_2016_1172961 crossref_primary_10_3892_or_2014_3477 crossref_primary_10_26508_lsa_202302411 crossref_primary_10_1089_jir_2014_0081 crossref_primary_10_1158_1078_0432_CCR_13_2492 crossref_primary_10_1158_1535_7163_MCT_14_0800 crossref_primary_10_18632_aging_103893 crossref_primary_10_18632_oncotarget_7272 crossref_primary_10_3390_ijms21113927 crossref_primary_10_1016_j_semcancer_2017_06_001 crossref_primary_10_1038_nri3896 crossref_primary_10_1016_S0140_6736_21_00438_4 crossref_primary_10_1038_onc_2015_150 crossref_primary_10_1016_j_smim_2013_12_006 crossref_primary_10_3389_fmolb_2021_763902 |
Cites_doi | 10.1016/j.ccr.2013.06.017 10.1042/bj20030407 10.1128/MCB.21.5.1621-1632.2001 10.1038/nrc2734 10.1074/jbc.M204865200 10.1158/1535-7163.MCT-11-0480 10.1016/j.ccr.2012.10.023 10.1053/j.gastro.2003.10.066 10.1038/leu.2010.289 10.1016/j.cell.2011.02.013 10.1016/j.ccr.2009.01.002 10.1016/j.critrevonc.2010.05.002 10.1038/nm1282 10.1371/journal.pone.0046869 10.1158/1078-0432.CCR-10-2694 10.1186/1747-1028-5-14 10.1097/CAD.0b013e328341185b 10.1038/nprot.2006.446 10.1016/j.ccr.2009.10.015 10.1038/5007 10.1172/JCI0215617 10.1111/j.1440-1746.2008.05671.x |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1158/1535-7163.mct-13-0583-t |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-8514 |
EndPage | 474 |
ExternalDocumentID | 10_1158_1535_7163_MCT_13_0583_T 24398427 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .55 123 18M 2FS 2WC 34G 39C 3O- 53G 5RE 5VS AAJMC ABOCM ACGFO ACIWK ACPRK ADBBV ADCOW AENEX AFHIN AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P GX1 H13 H~9 IH2 KQ8 L7B MVM NPM OK1 P2P QTD RCR RHF RHI TR2 W8F WHG WOQ X7M YBU ZGI ZXP AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c482t-a917201c071966fbf08df96be2a9a81000f79b61f917c706bea151826f0a772f3 |
ISSN | 1535-7163 |
IngestDate | Fri Oct 25 04:14:49 EDT 2024 Fri Nov 22 00:46:09 EST 2024 Tue Aug 27 13:48:40 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c482t-a917201c071966fbf08df96be2a9a81000f79b61f917c706bea151826f0a772f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://mct.aacrjournals.org/content/molcanther/13/2/468.full.pdf |
PMID | 24398427 |
PQID | 1499149234 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1499149234 crossref_primary_10_1158_1535_7163_MCT_13_0583_T pubmed_primary_24398427 |
PublicationCentury | 2000 |
PublicationDate | 2014-Feb 2014-02-01 20140201 |
PublicationDateYYYYMMDD | 2014-02-01 |
PublicationDate_xml | – month: 02 year: 2014 text: 2014-Feb |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Molecular cancer therapeutics |
PublicationTitleAlternate | Mol Cancer Ther |
PublicationYear | 2014 |
References | McFarland (2022060800262185800_bib19) 2011; 10 Jenkins (2022060800262185800_bib8) 2005; 11 Putoczki (2022060800262185800_bib13) 2013; 24 Britschgi (2022060800262185800_bib23) 2012; 22 Hanahan (2022060800262185800_bib16) 2011; 144 Yu (2022060800262185800_bib22) 2009; 9 Judd (2022060800262185800_bib15) 2004; 126 Sorriano (2022060800262185800_bib9) 1999; 21 Scuto (2022060800262185800_bib21) 2011; 25 Haftchenary (2022060800262185800_bib5) 2011; 22 Jarnicki (2022060800262185800_bib2) 2010; 5 Morikawa (2022060800262185800_bib18) 2011; 17 Couto (2022060800262185800_bib20) 2012; 7 Bromberg (2022060800262185800_bib1) 2002; 109 Hedvat (2022060800262185800_bib7) 2009; 16 Noor (2022060800262185800_bib6) 2011; 78 Alonzi (2022060800262185800_bib10) 2001; 21 Bollrath (2022060800262185800_bib3) 2009; 15 Becker (2022060800262185800_bib11) 2006; 1 Johnstone (2022060800262185800_bib14) 2002; 277 Heinrich (2022060800262185800_bib4) 2003; 374 Kim (2022060800262185800_bib17) 2009; 24 Thiem (2022060800262185800_bib12) 2013; 123 |
References_xml | – volume: 24 start-page: 257 year: 2013 ident: 2022060800262185800_bib13 article-title: Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically publication-title: Cancer Cell doi: 10.1016/j.ccr.2013.06.017 contributor: fullname: Putoczki – volume: 123 start-page: 767 year: 2013 ident: 2022060800262185800_bib12 article-title: mTORC1 inhibition restricts inflammation-associated gastrointestinal tumorigenesis in mice publication-title: J Clin Invest contributor: fullname: Thiem – volume: 374 start-page: 1 year: 2003 ident: 2022060800262185800_bib4 article-title: Principles of interleukin (IL)-6-type cytokine signalling and its regulation publication-title: Biochem J doi: 10.1042/bj20030407 contributor: fullname: Heinrich – volume: 21 start-page: 1621 year: 2001 ident: 2022060800262185800_bib10 article-title: Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver publication-title: Mol Cell Biol doi: 10.1128/MCB.21.5.1621-1632.2001 contributor: fullname: Alonzi – volume: 9 start-page: 798 year: 2009 ident: 2022060800262185800_bib22 article-title: STATs in cancer inflammation and immunity: a leading role for STAT3 publication-title: Nat Rev Cancer doi: 10.1038/nrc2734 contributor: fullname: Yu – volume: 277 start-page: 34531 year: 2002 ident: 2022060800262185800_bib14 article-title: Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms of gene expression publication-title: J Biol Chem doi: 10.1074/jbc.M204865200 contributor: fullname: Johnstone – volume: 10 start-page: 2384 year: 2011 ident: 2022060800262185800_bib19 article-title: Therapeutic potential of AZD1480 for the treatment of human glioblastoma publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-11-0480 contributor: fullname: McFarland – volume: 22 start-page: 796 year: 2012 ident: 2022060800262185800_bib23 article-title: JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer publication-title: Cancer Cell doi: 10.1016/j.ccr.2012.10.023 contributor: fullname: Britschgi – volume: 126 start-page: 196 year: 2004 ident: 2022060800262185800_bib15 article-title: Gastric cancer development in mice lacking the SHP2 biding site on the IL-6 family co-receptor gp130 publication-title: Gastroenterology doi: 10.1053/j.gastro.2003.10.066 contributor: fullname: Judd – volume: 25 start-page: 538 year: 2011 ident: 2022060800262185800_bib21 article-title: The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival publication-title: Leukemia doi: 10.1038/leu.2010.289 contributor: fullname: Scuto – volume: 144 start-page: 646 year: 2011 ident: 2022060800262185800_bib16 article-title: Hallmarks of cancer: the next generation publication-title: Cell doi: 10.1016/j.cell.2011.02.013 contributor: fullname: Hanahan – volume: 15 start-page: 91 year: 2009 ident: 2022060800262185800_bib3 article-title: gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis publication-title: Cancer Cell doi: 10.1016/j.ccr.2009.01.002 contributor: fullname: Bollrath – volume: 78 start-page: 33 year: 2011 ident: 2022060800262185800_bib6 article-title: Shooting the messenger: targeting signal transduction pathways in leukemia and related disorders publication-title: Crit Rev Oncol Hematol doi: 10.1016/j.critrevonc.2010.05.002 contributor: fullname: Noor – volume: 11 start-page: 845 year: 2005 ident: 2022060800262185800_bib8 article-title: Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling publication-title: Nat Med doi: 10.1038/nm1282 contributor: fullname: Jenkins – volume: 7 start-page: e46869 year: 2012 ident: 2022060800262185800_bib20 article-title: AZD1480 blocks growth and tumorigenesis of RET-activated thyroid cancer cell lines publication-title: PLoS ONE doi: 10.1371/journal.pone.0046869 contributor: fullname: Couto – volume: 17 start-page: 1452 year: 2011 ident: 2022060800262185800_bib18 article-title: STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-10-2694 contributor: fullname: Morikawa – volume: 5 start-page: 14 year: 2010 ident: 2022060800262185800_bib2 article-title: Stat3: linking inflammation to epithelial cancer—more than a “gut” feeling? publication-title: Cell Div doi: 10.1186/1747-1028-5-14 contributor: fullname: Jarnicki – volume: 22 start-page: 115 year: 2011 ident: 2022060800262185800_bib5 article-title: Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report publication-title: Anticancer Drugs doi: 10.1097/CAD.0b013e328341185b contributor: fullname: Haftchenary – volume: 1 start-page: 2900 year: 2006 ident: 2022060800262185800_bib11 article-title: High resolution colonoscopy in live mice publication-title: Nat Protoc doi: 10.1038/nprot.2006.446 contributor: fullname: Becker – volume: 16 start-page: 487 year: 2009 ident: 2022060800262185800_bib7 article-title: The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors publication-title: Cancer Cell doi: 10.1016/j.ccr.2009.10.015 contributor: fullname: Hedvat – volume: 21 start-page: 70 year: 1999 ident: 2022060800262185800_bib9 article-title: Generalized lacZ expression with the ROSA26 Cre reporter strain publication-title: Nat Genet doi: 10.1038/5007 contributor: fullname: Sorriano – volume: 109 start-page: 1139 year: 2002 ident: 2022060800262185800_bib1 article-title: Stat proteins and oncogenesis publication-title: J Clin Invest doi: 10.1172/JCI0215617 contributor: fullname: Bromberg – volume: 24 start-page: 646 year: 2009 ident: 2022060800262185800_bib17 article-title: STAT3 expression in gastric cancer indicates a poor prognosis publication-title: J Gastroenterol Hepatol doi: 10.1111/j.1440-1746.2008.05671.x contributor: fullname: Kim |
SSID | ssj0018921 |
Score | 2.3076696 |
Snippet | Aberrant activation of the latent transcription factor STAT3 and its downstream targets is a common feature of epithelial-derived human cancers, including... |
SourceID | proquest crossref pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 468 |
SubjectTerms | Animals Apoptosis - drug effects Apoptosis - genetics Blotting, Western Cell Proliferation - drug effects Colonic Neoplasms - genetics Colonic Neoplasms - metabolism Colonic Neoplasms - prevention & control Cytokine Receptor gp130 - genetics Cytokine Receptor gp130 - metabolism Disease Progression Epithelium - drug effects Epithelium - metabolism Epithelium - pathology Gastrointestinal Neoplasms - genetics Gastrointestinal Neoplasms - metabolism Gastrointestinal Neoplasms - prevention & control Gene Expression - drug effects Humans Immunohistochemistry Janus Kinase 1 - antagonists & inhibitors Janus Kinase 1 - metabolism Janus Kinase 2 - antagonists & inhibitors Janus Kinase 2 - metabolism Mice, 129 Strain Mice, Inbred C57BL Mice, Knockout Mice, Transgenic Proliferating Cell Nuclear Antigen - metabolism Pyrazoles - pharmacology Pyrimidines - pharmacology Reverse Transcriptase Polymerase Chain Reaction STAT3 Transcription Factor - genetics STAT3 Transcription Factor - metabolism Tumor Burden - drug effects Tumor Burden - genetics |
Title | Therapeutic inhibition of Jak activity inhibits progression of gastrointestinal tumors in mice |
URI | https://www.ncbi.nlm.nih.gov/pubmed/24398427 https://search.proquest.com/docview/1499149234 |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagSIgL4s2Wh4LErUrJw9l1jlBApWi5kEo9ETmOTSOUpOo6l_76zviRpAsrARdrlfHaq5lvJzP2PAh5S1MeRxJv_esoCqmo47CSmYChAmNfyZozTBRef1sen9KTs-xsOswx2SW6OhRXf8wr-R-pwjOQK2bJ_oNkx0XhAXwG-cIIEobxb2Xsk6cOmu68qRpv_53wX6ZMhukM4UgbG4xlC3HgpJ98oy97LBgB_3MTdT602Hun6Q5aFxLn7da176KLUWJCmshEv_VolX_XGCFqtGs7qfsPA-JCb8foozoedC-ubN9seGeK8XS_OG9k62LQlIOvO5mIqQ9mxhfLpE3BpKM31G06g1Uy053U9tf5XadnmKcAa2UhOHfpYSt0iC0pMpaGev4NEM5Fa0SdgJnFqC06sFVO25NukztYOxHbLXz88nW8eGJ5ErswQNj33Y5dsYS0W-emPbPDSTHGSvGA3HdeRvDeQuYhuSW7R-Tu2sVRPCY_ZsgJJuQEvQoAOYFHjidtghlycNI2cgKLHJgfIHKekNPPn4qj49B12ggFZYkOOTjtIEEB9ia4v6pSEatVvqxkwnPO8ApIrfJqGSuYJ1YREDhYiuCZqoiDe6bSp2Sv6zv5nMAvZPGKJ6wGBUAFW-XRUmSRiDOYSutaLUjk-VVe2IIqpXFEM1Yit0vkdrk-Kso4LZHbZbEgbzxfS1B-eKPFO9kPG_Bbwb3BEoN0QZ5Zho-LegHt76S8IPcm2L4ke_pykK_AxNTVawOKa4Clfgo |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Therapeutic+inhibition+of+Jak+activity+inhibits+progression+of+gastrointestinal+tumors+in+mice&rft.jtitle=Molecular+cancer+therapeutics&rft.au=Stuart%2C+Emma&rft.au=Buchert%2C+Michael&rft.au=Putoczki%2C+Tracy&rft.au=Thiem%2C+Stefan&rft.date=2014-02-01&rft.eissn=1538-8514&rft.volume=13&rft.issue=2&rft.spage=468&rft_id=info:doi/10.1158%2F1535-7163.mct-13-0583-t&rft_id=info%3Apmid%2F24398427&rft.externalDocID=24398427 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1535-7163&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1535-7163&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1535-7163&client=summon |